CoChat
Sign Up
Cited by 0Adenosine and Purinergic SignalingIon channel regulation and functionReceptor Mechanisms and Signaling

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists

Open access
Sheng, Danqi, Yue, Chen-Xi, Jin, Fei, Wang, Yao, Ichikawa, Muneyoshi, Yu, Ye, Guo, Chang-Run, Hattori, Motoyuki·2024·eLife
DOI 10.7554/elife.92829.3

Published version of a preprint

Open this paper in CoChat — free account

Abstract

P2X receptors are extracellular ATP-gated ion channels that form homo- or heterotrimers and consist of seven subtypes. They are expressed in various tissues, including neuronal and nonneuronal cells, and play critical roles in physiological processes such as neurotransmission, inflammation, pain, and cancer. As a result, P2X receptors have attracted considerable interest as drug targets, and various competitive inhibitors have been developed. However, although several P2X receptor structures from different subtypes have been reported, the limited structural information of P2X receptors in complex with competitive antagonists hampers the understanding of orthosteric inhibition, hindering the further design and optimization of those antagonists for drug discovery. We determined the cryogenic electron microscopy (cryo-EM) structures of the mammalian P2X7 receptor in complex with two classical competitive antagonists of pyridoxal-5'-phosphate derivatives, pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) (PPNDS) and pyridoxal phosphate-6-azophenyl-2′,5′-disulfonic acid (PPADS), and performed structure-based mutational analysis by patch-clamp recording as well as molecular dynamics (MD) simulations. Our structures revealed the orthosteric site for PPADS/PPNDS, and structural comparison with the previously reported apo- and ATP-bound structures showed how PPADS/PPNDS binding inhibits the conformational changes associated with channel activation. In addition, structure-based mutational analysis identified key residues involved in the PPNDS sensitivity of P2X1 and P2X3, which are known to have higher affinity for PPADS/PPNDS than other P2X subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.92829.3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. Banks, 2005, Integrated Modeling Program, Applied Chemical Theory (IMPACT), Journal of Computational Chemistry, 26, 1752, 10.1002/jcc.20292 · DOI
  2. Bodnar, 2011, Amino acid residues constituting the agonist binding site of the human P2X3 receptor, The Journal of Biological Chemistry, 286, 2739, 10.1074/jbc.M110.167437 · DOI
  3. Brake, 1994, New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor, Nature, 371, 519, 10.1038/371519a0 · DOI
  4. Brown, 2001, Actions of a series of PPADS analogs at P2X(1) and P2X(3) receptors, Drug Development Research, 53, 281, 10.1002/ddr.1197 · DOI
  5. Buell, 1996, An antagonist-insensitive P2X receptor expressed in epithelia and brain, The EMBO Journal, 15, 55, 10.1002/j.1460-2075.1996.tb00333.x · DOI
  6. Burnstock, 1972, Purinergic nerves, Pharmacological Reviews, 24, 509, 10.1016/S0031-6997(25)06930-3 · DOI · Paper page
  7. Burnstock, 2014, ATP-gated P2X receptors in health and disease, Frontiers in Cellular Neuroscience, 8, 10.3389/fncel.2014.00204 · DOI
  8. Chen, 1995, A P2X purinoceptor expressed by A subset of sensory neurons, Nature, 377, 428, 10.1038/377428a0 · DOI
  9. Cho, 2013, Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators, European Journal of Medicinal Chemistry, 70, 811, 10.1016/j.ejmech.2013.10.026 · DOI
  10. Cui, 2022, P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough, Computational and Structural Biotechnology Journal, 20, 1642, 10.1016/j.csbj.2022.03.030 · DOI
  11. Donnelly-Roberts, 2009, Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors, British Journal of Pharmacology, 157, 1203, 10.1111/j.1476-5381.2009.00233.x · DOI
  12. Dror, 2011, Activation mechanism of the β2-adrenergic receptor, PNAS, 108, 18684, 10.1073/pnas.1110499108 · DOI
  13. Emsley, 2010, Features and development of Coot, Acta Crystallographica. Section D, Biological Crystallography, 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
  14. Ennion, 2000, The role of positively charged amino acids in ATP recognition by human P2X(1) receptors, The Journal of Biological Chemistry, 275, 29361, 10.1074/jbc.M003637200 · DOI
  15. Garcia-Guzman, 1997, Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue, Molecular Pharmacology, 51, 109, 10.1124/mol.51.1.109 · DOI
  16. Hattori, 2012, Molecular mechanism of ATP binding and ion channel activation in P2X receptors, Nature, 485, 207, 10.1038/nature11010 · DOI
  17. Huo, 2018, Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region, The Journal of Biological Chemistry, 293, 12820, 10.1074/jbc.RA118.003737 · DOI
  18. Illes, 2021, Update of P2X receptor properties and their pharmacology: IUPHAR Review 30, British Journal of Pharmacology, 178, 489, 10.1111/bph.15299 · DOI
  19. Jacobson, 2002, Purine and pyrimidine (P2) receptors as drug targets, Journal of Medicinal Chemistry, 45, 4057, 10.1021/jm020046y · DOI
  20. Jiang, 2000, Identification of amino acid residues contributing to the ATP-binding site of a purinergic P2X receptor, The Journal of Biological Chemistry, 275, 34190, 10.1074/jbc.M005481200 · DOI
  21. Jones, 2000, Functional characterization of the P2X(4) receptor orthologues, British Journal of Pharmacology, 129, 388, 10.1038/sj.bjp.0703059 · DOI
  22. Jorgensen, 1996, Development and testing of the OPLS All-atom force field on conformational energetics and properties of organic liquids, Journal of the American Chemical Society, 118, 11225, 10.1021/ja9621760 · DOI
  23. Jung, 2013, Synthesis and structure–activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists, Bioorganic & Medicinal Chemistry, 21, 2643, 10.1016/j.bmc.2013.01.073 · DOI
  24. Kaczmarek-Hájek, 2012, Molecular and functional properties of P2X receptors--recent progress and persisting challenges, Purinergic Signalling, 8, 375, 10.1007/s11302-012-9314-7 · DOI
  25. Kaminski, 2001, Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides, The Journal of Physical Chemistry B, 105, 6474, 10.1021/jp003919d · DOI
  26. Karasawa, 2016, Structural basis for subtype-specific inhibition of the P2X7 receptor, eLife, 5, 10.7554/eLife.22153 · DOI
  27. Kasuya, 2016, structural insights into divalent cation modulations of ATP-gated P2X receptor channels, Cell Reports, 14, 932, 10.1016/j.celrep.2015.12.087 · DOI
  28. Kasuya, 2017, Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel, Nature Communications, 8, 10.1038/s41467-017-00887-9 · DOI
  29. Kawate, 2009, Crystal structure of the ATP-gated P2X(4) ion channel in the closed state, Nature, 460, 592, 10.1038/nature08198 · DOI
  30. Khakh, 2006, P2X receptors as cell-surface ATP sensors in health and disease, Nature, 442, 527, 10.1038/nature04886 · DOI
  31. Kim, 2001, Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors, Journal of Medicinal Chemistry, 44, 340, 10.1021/jm9904203 · DOI
  32. Lambrecht, 2000, The novel pyridoxal-5’-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors, European Journal of Pharmacology, 387, R19, 10.1016/s0014-2999(99)00834-1 · DOI
  33. Lambrecht, 2002, Structure-activity relationships of suramin and pyridoxal-5’-phosphate derivatives as P2 receptor antagonists, Current Pharmaceutical Design, 8, 2371, 10.2174/1381612023392973 · DOI
  34. Li, 2018, Molecular mechanism underlying the subtype-selectivity of competitive inhibitor NF110 and its distinct potencies in human and rat P2X3 receptors, Science Bulletin, 63, 1616, 10.1016/j.scib.2018.11.016 · DOI
  35. Li, 2019, Molecular mechanisms of human P2X3 receptor channel activation and modulation by divalent cation bound ATP, eLife, 8, 10.7554/eLife.47060 · DOI
  36. Liebschner, 2019, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix, Acta Crystallographica. Section D, Structural Biology, 75, 861, 10.1107/S2059798319011471 · DOI · Paper page
  37. Lomize, 2012, OPM database and PPM web server: resources for positioning of proteins in membranes, Nucleic Acids Research, 40, D370, 10.1093/nar/gkr703 · DOI
  38. Lörinczi, 2012, Involvement of the cysteine-rich head domain in activation and desensitization of the P2X1 receptor, PNAS, 109, 11396, 10.1073/pnas.1118759109 · DOI
  39. Mansoor, 2016, X-ray structures define human P2X(3) receptor gating cycle and antagonist action, Nature, 538, 66, 10.1038/nature19367 · DOI
  40. McCarthy, 2019, Full-Length P2X7 structures reveal how palmitoylation prevents channel desensitization, Cell, 179, 659, 10.1016/j.cell.2019.09.017 · DOI
  41. McGarvey, 2022, Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic COUGH and unexplained chronic COUGH (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials, Lancet, 399, 909, 10.1016/S0140-6736(21)02348-5 · DOI
  42. Michel, 2008, Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects, British Journal of Pharmacology, 155, 738, 10.1038/bjp.2008.306 · DOI
  43. Mirdita, 2022, ColabFold: making protein folding accessible to all, Nature Methods, 19, 679, 10.1038/s41592-022-01488-1 · DOI · Paper page
  44. North, 2000, Pharmacology of cloned P2X receptors, Annual Review of Pharmacology and Toxicology, 40, 563, 10.1146/annurev.pharmtox.40.1.563 · DOI
  45. North, 2002, Molecular physiology of P2X receptors, Physiological Reviews, 82, 1013, 10.1152/physrev.00015.2002 · DOI · Paper page
  46. Pettersen, 2004, UCSF Chimera--A visualization system for exploratory research and analysis, Journal of Computational Chemistry, 25, 1605, 10.1002/jcc.20084 · DOI
  47. Punjani, 2020, Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction, Nature Methods, 17, 1214, 10.1038/s41592-020-00990-8 · DOI
  48. Ralevic, 1998, Receptors for purines and pyrimidines, Pharmacological Reviews, 50, 413, 10.1016/S0031-6997(24)01373-5 · DOI
  49. Robert, 2014, Deciphering key features in protein structures with the new ENDscript server, Nucleic Acids Research, 42, W320, 10.1093/nar/gku316 · DOI · Paper page
  50. Rohou, 2015, CTFFIND4: Fast and accurate defocus estimation from electron micrographs, Journal of Structural Biology, 192, 216, 10.1016/j.jsb.2015.08.008 · DOI
  51. Shen, 2023, Structural insights into the allosteric inhibition of P2X4 receptors, Nature Communications, 14, 10.1038/s41467-023-42164-y · DOI · Paper page
  52. Sheng, 2022, Recent progress in the structural biology of P2X receptors, Proteins, 90, 1779, 10.1002/prot.26302 · DOI
  53. Sievers, 2018, Clustal Omega for making accurate alignments of many protein sequences, Protein Science, 27, 135, 10.1002/pro.3290 · DOI · Paper page
  54. Sun, 2022, Vanilloid agonist-mediated activation of TRPV1 channels requires coordinated movement of the S1-S4 bundle rather than a quiescent state, Science Bulletin, 67, 1062, 10.1016/j.scib.2022.02.016 · DOI
  55. Valera, 1994, A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP, Nature, 371, 516, 10.1038/371516a0 · DOI
  56. Wang, 2017, Intersubunit physical couplings fostered by the left flipper domain facilitate channel opening of P2X4 receptors, The Journal of Biological Chemistry, 292, 7619, 10.1074/jbc.M116.771121 · DOI
  57. Wang, 2018, Druggable negative allosteric site of P2X3 receptors, PNAS, 115, 4939, 10.1073/pnas.1800907115 · DOI
  58. Wu, 2019, High-quality, high-throughput cryo-electron microscopy data collection via beam tilt and astigmatism-free beam-image shift, Journal of Structural Biology, 208, 10.1016/j.jsb.2019.09.013 · DOI
  59. Zhang, 2022, Dynamic recognition of naloxone, morphine and endomorphin1 in the same pocket of µ-opioid receptors, Frontiers in Molecular Biosciences, 9, 10.3389/fmolb.2022.925404 · DOI
  60. Zhao, 2014, Relative motions between left flipper and dorsal fin domains favour P2X4 receptor activation, Nature Communications, 5, 10.1038/ncomms5189 · DOI
  61. Zheng, 2017, MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy, Nature Methods, 14, 331, 10.1038/nmeth.4193 · DOI
  62. Zivanov, 2018, New tools for automated high-resolution cryo-EM structure determination in RELION-3, eLife, 7, 10.7554/eLife.42166 · DOI
  63. Sheng D, Hattori M. 2023. Cryo-EM structures of the panda P2X7 receptor in complex with PPNDS. RCSB Protein Data Bank. https://www.rcsb.org/structure/8JV8. 8JV8.
  64. Sheng D, Hattori M. 2023. Cryo-EM structures of the panda P2X7 receptor in complex with PPADS. RCSB Protein Data Bank. https://www.rcsb.org/structure/8JV7. 8JV7.
  65. Sheng D, Yue CX, Jin F, Wang Y, Ichikawa M, Yu Y, Guo CR, Hattori M. 2023. Electrophysiology of P2X receptors and their mutants. Science Data Bank. · DOI

Metadata

Authors
Sheng, D., Yue, C.-X., Jin, F., Wang, Y., Ichikawa, M., Yu, Y., Guo, C.-R., & Hattori, M.
Affiliations
  • Fudan University (CN)
  • China Pharmaceutical University (CN)
ORCID
Venue
eLife
Publisher
eLife Sciences Publications, Ltd
Published
2024-04-05
Volume
12
ISSN
2050-084X (ISSN-L)
DOI
10.7554/elife.92829.3
OpenAlex
W4393995626
Cited by
0
References
1
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
eLife (publishedVersion, cc-by)
Funders
  • National Natural Science Foundation of China (32071234, 32271244, 32250610205)
  • Shanghai Municipal Education Commission (ZDSYS14005)
  • Japan Science and Technology Agency (10.52926/JPMJPR20E1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
P2X receptors, P2X7 receptor, competitive antagonists, PPADS, ATP-gated ion channels, receptor structure, channel activation, P2X1, P2X3 receptor, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review